Template:Pyelonephritis antibiotics: Difference between revisions
No edit summary |
|||
| Line 2: | Line 2: | ||
====Outpatient==== | ====Outpatient==== | ||
''Consider one dose of [[Ceftriaxone]] 1g IV or [[Gentamycin]] 7mg/kg IV if the regional susceptibility of [[TMP/SMX]] or [[Fluoroquinolones]] is <80%'' | ''Consider one dose of [[Ceftriaxone]] 1g IV or [[Gentamycin]] 7mg/kg IV if the regional susceptibility of [[TMP/SMX]] or [[Fluoroquinolones]] is <80%'' | ||
*[[Ciprofloxacin]] 500mg BID | *[[Ciprofloxacin]] 500mg PO BID x7 days '''OR''' | ||
*[[Cefpodoxime]] | *[[Cefpodoxime]] 200mg PO BID x10-14 days '''OR'''<ref>Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.</ref> | ||
*[[Levofloxacin]] 750mg PO | *[[Levofloxacin]] 750mg PO QD x7 days<ref>Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.</ref> | ||
====Adult Inpatient Options==== | ====Adult Inpatient Options==== | ||
*[[Ciprofloxacin]] 400mg IV q12hr OR | *[[Ciprofloxacin]] 400mg IV q12hr '''OR''' | ||
*[[Ceftriaxone]] 1gm IV QD OR | *[[Ceftriaxone]] 1gm IV QD '''OR''' | ||
*Cefotaxime 1-2gm IV q8hr OR | *Cefotaxime 1-2gm IV q8hr '''OR''' | ||
*[[Gentamicin]] 3mg/kg/day divided q8hr +/- [[ampicillin]] 1–2 gm q4hr OR | *[[Gentamicin]] 3mg/kg/day divided q8hr +/- [[ampicillin]] 1–2 gm q4hr '''OR''' | ||
*[[Piperacillin/Tazobactam]] 3.375 gm IV q6hr OR | *[[Piperacillin/Tazobactam]] 3.375 gm IV q6hr '''OR''' | ||
*[[Cefepime]] 2gm IV q8hr OR | *[[Cefepime]] 2gm IV q8hr '''OR''' | ||
*[[Imipenem]] 500mg IV q8hr | *[[Imipenem]] 500mg IV q8hr | ||
====Pediatric Inpatient Options==== | ====Pediatric Inpatient Options==== | ||
*[[Ceftriaxone]] 75mg/kg IV | *[[Ceftriaxone]] 75mg/kg IV QD '''OR''' | ||
*[[Cefotaxime]] 50mg/kg IV q8hrs | *[[Cefotaxime]] 50mg/kg IV q8hrs '''OR''' | ||
*[[Ampicillin]] 25mg/kg IV q6hrs + [[Gentamicin]] 2.5mg/kg IV q8hrs | *[[Ampicillin]] 25mg/kg IV q6hrs '''+''' [[Gentamicin]] 2.5mg/kg IV q8hrs | ||
Revision as of 20:05, 19 November 2017
Treatment is targeted at E. coli, Enterococcus, Klebsiella, Proteus mirabilis, S. saprophyticus
Outpatient
Consider one dose of Ceftriaxone 1g IV or Gentamycin 7mg/kg IV if the regional susceptibility of TMP/SMX or Fluoroquinolones is <80%
- Ciprofloxacin 500mg PO BID x7 days OR
- Cefpodoxime 200mg PO BID x10-14 days OR[1]
- Levofloxacin 750mg PO QD x7 days[2]
Adult Inpatient Options
- Ciprofloxacin 400mg IV q12hr OR
- Ceftriaxone 1gm IV QD OR
- Cefotaxime 1-2gm IV q8hr OR
- Gentamicin 3mg/kg/day divided q8hr +/- ampicillin 1–2 gm q4hr OR
- Piperacillin/Tazobactam 3.375 gm IV q6hr OR
- Cefepime 2gm IV q8hr OR
- Imipenem 500mg IV q8hr
Pediatric Inpatient Options
- Ceftriaxone 75mg/kg IV QD OR
- Cefotaxime 50mg/kg IV q8hrs OR
- Ampicillin 25mg/kg IV q6hrs + Gentamicin 2.5mg/kg IV q8hrs
- ↑ Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.
- ↑ Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.